Announcement • Sep 06

Matinas Biopharma Holdings, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

On August 31, 2026, Matinas BioPharma Holdings, Inc. (the Company) received written notice (the Notice) from the NYSE American LLC (the NYSE American) that it is not in compliance with the continued listing standard set forth in Section 1003(a)(i) of the NYSE American Company Guide (the Company Guide), which requires a company to have stockholders' equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years. The noncompliance was based on the Company's reported stockholders' equity of $1.8 million as of June 30, 2026 and losses from continuing operations and/or net losses in its five most recent fiscal years. As previously disclosed under Item 3.01 of the Current Reports on Form 8-K filed with the Securities and Exchange Commission on April 3, 2026 and June 26, 2026, the Company also received written notices from the NYSE American indicating that the Company was not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) and 1003(a)(iii) of the Company Guide. Section 1003(a)(ii) requires a company to have stockholders' equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. Section 1003(a)(iii) requires a company to have stockholders' equity of at least $6.0 million if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years. On May 4, 2026, the Company submitted a plan (the Plan) to the NYSE American advising of actions it has taken or will take to regain compliance with the continued listing standards. As previously disclosed, the NYSE American accepted the Plan and granted the Company a plan period through October 2, 2027 (the Plan Period, and such date, the Plan Period Deadline) to regain compliance with the continued listing standards. If the Company is not in compliance with all stockholders' equity standards by the Plan Period Deadline, or does not make progress consistent with the Plan during the Plan Period, the NYSE American will initiate delisting proceedings as appropriate. The Company may appeal a staff delisting determination in accordance with Section 1010 and Part 12 of the Company Guide. The Notice has no immediate impact on the listing of the Company's shares of common stock, which will continue to be listed and traded on the NYSE American during the Plan Period, subject to the Company's compliance with the other listing requirements of the NYSE American. The Company will continue to be included in the list of NYSE American noncompliant issuers, and the common stock will continue to trade under the symbol MTNB. The .BC indicator will continue to be disseminated with the Company's ticker symbol. The .BC indicator will be removed when the Company has regained compliance with all applicable continued listing standards. The Notice does not affect the Company's ongoing business operations or its reporting requirements with the Securities and Exchange Commission.

Matinas BioPharma Holdings, Inc. Stock Price

MTNB Share Price Performance

MTNB Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

Matinas BioPharma Holdings, Inc. Key Details

About MTNB

Recent MTNB News & Updates

Matinas Biopharma Holdings, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

New major risk - Shareholder dilution

New major risk - Share price stability

Recent updates

Matinas BioPharma Holdings, Inc. Competitors

Panacea Life Sciences Holdings

Cardio Diagnostics Holdings

InMed Pharmaceuticals

NuCana